AI Article Synopsis
- - The HER2-enriched intrinsic subtype accounts for around 75% of HER2-positive, hormone receptor-negative breast cancer, and optimizing therapy in this group may reduce the need for toxic anthracycline chemotherapy
- - The DECRESCENDO trial (NCT04675827) is a major phase II study focusing on early HER2-positive, HR-negative breast cancer, testing a combination of pertuzumab and trastuzumab with chemotherapy before proceeding to adjuvant treatment
- - The main goal of the trial is to assess the 3-year recurrence-free survival rate and offers a unique care model allowing some patients to receive their post-surgery treatment outside the hospital setting
Article Abstract
The human epidermal growth factor receptor 2 (HER2)-enriched intrinsic subtype represents up to 75% of all HER2-positive hormone receptor (HR)-negative breast cancer (BC). Optimizing HER2-targeting therapy in this population might allow the omission of anthracycline-based chemotherapy, which is associated with potentially severe toxicities. DECRESCENDO (NCT04675827) is a large, multicenter, single-arm phase II trial in patients with HR-negative, HER2-positive, node-negative early BC evaluating a neoadjuvant pertuzumab and trastuzumab fixed-dose combination administered subcutaneously plus taxane-based chemotherapy followed by adjuvant treatment, adapted according to response to neoadjuvant therapy. The primary end point is the 3-year recurrence-free survival rate in patients with 'HER2-enriched' tumors and a pathological complete response. This flexible care substudy offers adjuvant treatment administration outside the hospital to some patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2022-1282 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!